Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study
Hokyou Lee, Yong‐ho Lee, Seung Up Kim, et al.
Clinical Gastroenterology and Hepatology (2020) Vol. 19, Iss. 10, pp. 2138-2147.e10
Closed Access | Times Cited: 364

Showing 1-25 of 364 citing articles:

Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis
Alessandro Mantovani, Alessandro Csermely, Graziana Petracca, et al.
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 11, pp. 903-913
Open Access | Times Cited: 385
Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach
Giovanni Targher, Herbert Tilg, Christopher D. Byrne
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 7, pp. 578-588
Open Access | Times Cited: 371
Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States
Donghee Kim, Peter Konyn, Keeryth K. Sandhu, et al.
Journal of Hepatology (2021) Vol. 75, Iss. 6, pp. 1284-1291
Closed Access | Times Cited: 328
Global Impacts of Western Diet and Its Effects on Metabolism and Health: A Narrative Review
Vicente Javier Clemente‐Suárez, Ana Isabel Beltrán-Velasco, Laura Redondo-Flórez, et al.
Nutrients (2023) Vol. 15, Iss. 12, pp. 2749-2749
Open Access | Times Cited: 277
MAFLD: How is it different from NAFLD?
Cameron Gofton, Yadhavan Upendran, Ming‐Hua Zheng, et al.
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. Suppl, pp. S17-S31
Open Access | Times Cited: 233
Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement
Mohammed Eslam, Naim Alkhouri, Pietro Vajro, et al.
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 10, pp. 864-873
Closed Access | Times Cited: 207
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 195
Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals
Kai En Chan, Tiffany Jia Ling Koh, Ansel Shao Pin Tang, et al.
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 107, Iss. 9, pp. 2691-2700
Open Access | Times Cited: 188
Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD
Vy H. Nguyen, Michael H. Le, Ramsey Cheung, et al.
Clinical Gastroenterology and Hepatology (2021) Vol. 19, Iss. 10, pp. 2172-2181.e6
Closed Access | Times Cited: 172
The associations between modifiable risk factors and nonalcoholic fatty liver disease: A comprehensive Mendelian randomization study
Jiarong Xie, Hangkai Huang, Zhening Liu, et al.
Hepatology (2022) Vol. 77, Iss. 3, pp. 949-964
Open Access | Times Cited: 158
MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach
Tsubasa Tsutsumi, Mohammed Eslam, Takumi Kawaguchi, et al.
Hepatology Research (2021) Vol. 51, Iss. 11, pp. 1115-1128
Closed Access | Times Cited: 153
Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases
Jorge Gutiérrez‐Cuevas, Arturo Santos, Juan Armendáriz‐Borunda
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11629-11629
Open Access | Times Cited: 145
Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review
Luca Rinaldi, Pia Clara Pafundi, Raffaele Galiero, et al.
Antioxidants (2021) Vol. 10, Iss. 2, pp. 270-270
Open Access | Times Cited: 136
Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China
Yebei Liang, Hongli Chen, Yuexing Liu, et al.
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 1, pp. 88-97
Open Access | Times Cited: 136
Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver
Eda Kaya, Yusuf Yılmaz
Journal of Clinical and Translational Hepatology (2021) Vol. 10, Iss. 2, pp. 329-338
Open Access | Times Cited: 120
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention
Xiaodong Zhou, Jingjing Cai, Giovanni Targher, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 98
An international multidisciplinary consensus statement on MAFLD and the risk of CVD
Xiaodong Zhou, Giovanni Targher, Christopher D. Byrne, et al.
Hepatology International (2023) Vol. 17, Iss. 4, pp. 773-791
Open Access | Times Cited: 87
Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
Hyeok‐Hee Lee, Han Ah Lee, Eun-Jin Kim, et al.
Gut (2023), pp. gutjnl-331003
Closed Access | Times Cited: 82
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
Gi‐Ae Kim, Joon Ho Moon, Won Kim
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 4, pp. 831-843
Open Access | Times Cited: 67
An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease
Dan‐Qin Sun, Giovanni Targher, Christopher D. Byrne, et al.
HepatoBiliary Surgery and Nutrition (2023) Vol. 12, Iss. 3, pp. 386-403
Open Access | Times Cited: 55
Natural history of metabolic dysfunction-associated steatotic liver disease
Vasileios Lekakis, George Papatheodoridis
European Journal of Internal Medicine (2023) Vol. 122, pp. 3-10
Closed Access | Times Cited: 54
Epidemiology of Metabolic Dysfunction Associated Steatotic Liver Disease
Zobair M. Younossi, Markos Kalligeros, Linda Henry
Clinical and Molecular Hepatology (2024)
Open Access | Times Cited: 36
MAFLD predicts cardiovascular disease risk better than MASLD
Ziyan Pan, Gamal Shiha, Gamal Esmat, et al.
Liver International (2024) Vol. 44, Iss. 7, pp. 1567-1574
Closed Access | Times Cited: 33
Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies
Mohammad Habibullah, Khaleed Jemmieh, Amr Ouda, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 29
MAFLD: Renovation of clinical practice and disease awareness of fatty liver
Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, et al.
Hepatology Research (2021) Vol. 52, Iss. 5, pp. 422-432
Closed Access | Times Cited: 90
Page 1 - Next Page

Scroll to top